|
Treatment Group |
Treatment Group |
Treatment Group |
Treatment
Group |
Treatment Response
|
Total (N=76)
n (%)
|
Sirolimus (N=51)
n (%)
|
Vincristine (N=25)
n (%)
|
p-value
|
Any response at 3 months |
53/63 (84.1%) |
30/39 (76.9%) |
23/24
(95.8%) |
0.074 |
HemR at 3 months |
26/27 (96.3%) |
11/12 (91.7%) |
15/15 (100%) |
0.4 |
RadR at 3 months |
10/21 (47.6%) |
2/10 (20%) |
8/11 (72.7%) |
0.030 |
ClinR at 3 months |
50/57 (87.7%) |
28/34 (82.4%) |
22/23 (95.7%) |
0.2 |
Any response at 6 months |
61/70 (87.1%) |
38/46 (82.6%) |
23/24
(95.8%) |
0.2 |
HemR at 6 months |
30/31 (96.8%) |
15/16 (93.8%) |
15/15 (100%) |
>0.9 |
RadR at 6 months |
27/38 (71.1%) |
17/25 (68%) |
10/13 (76.9%) |
0.7 |
ClinR at 6 months |
59/66 (89.4%) |
36/42 (85.7%) |
23/24 (95.8%) |
0.4 |